Published in J Urol on April 01, 2004
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet (2011) 8.81
Risks and benefits of bisphosphonates. Br J Cancer (2008) 1.57
Emerging novel therapies in the treatment of castrate-resistant prostate cancer. Can Urol Assoc J (2011) 1.04
Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease. Br J Cancer (2005) 1.01
Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis. Curr Med Res Opin (2010) 0.88
Health state utilities for skeletal-related events secondary to bone metastases. Eur J Health Econ (2013) 0.82
Economic Evaluation alongside Multinational Studies: A Systematic Review of Empirical Studies. PLoS One (2015) 0.77
Re: Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. J Urol (2004) 0.75
Cost-Effectiveness of Zoledronic Acid to Prevent and Treat Postmenopausal Osteoporosis in Comparison with Routine Medical Treatment. Electron Physician (2016) 0.75
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
Ethical and scientific implications of the globalization of clinical research. N Engl J Med (2009) 11.42
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet (2011) 8.81
Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med (2012) 8.64
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA (2006) 7.81
Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med (2009) 6.67
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2012) 6.49
Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA (2009) 6.36
Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol (2010) 4.50
A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol (2007) 4.37
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer (2012) 4.29
Pay for performance, quality of care, and outcomes in acute myocardial infarction. JAMA (2007) 3.79
Inappropriate prescribing for elderly Americans in a large outpatient population. Arch Intern Med (2004) 3.64
Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. Am Heart J (2009) 3.57
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol (2013) 3.38
Heart failure and a controlled trial investigating outcomes of exercise training (HF-ACTION): design and rationale. Am Heart J (2007) 3.34
Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patient communication. J Clin Oncol (2003) 3.31
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol (2005) 3.31
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol (2005) 3.22
Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation (2009) 3.18
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol (2014) 3.16
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer (2007) 3.15
eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci U S A (2010) 3.13
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst (2005) 3.08
The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients. Int J Radiat Oncol Biol Phys (2010) 3.06
Cost of cancer care: issues and implications. J Clin Oncol (2007) 3.00
Long-term outcomes and costs of ventricular assist devices among Medicare beneficiaries. JAMA (2008) 2.96
Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials.gov. JAMA Intern Med (2013) 2.86
Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer (2008) 2.86
Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA (2009) 2.83
Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol (2009) 2.83
Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. JAMA (2007) 2.75
Stage migration, selection bias, and survival associated with the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2003. J Clin Oncol (2012) 2.72
Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol (2009) 2.72
Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006. JAMA (2010) 2.68
Incidence and prevalence of heart failure in elderly persons, 1994-2003. Arch Intern Med (2008) 2.65
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int (2010) 2.59
Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol (2009) 2.58
Patient and implanting physician factors associated with mortality and complications after implantable cardioverter-defibrillator implantation, 2002-2005. Circ Arrhythm Electrophysiol (2008) 2.55
Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol (2013) 2.52
Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience. BJU Int (2012) 2.47
Resource use in the last 6 months of life among medicare beneficiaries with heart failure, 2000-2007. Arch Intern Med (2010) 2.28
Economic return of clinical trials performed under the pediatric exclusivity program. JAMA (2007) 2.28
Relationship between patient satisfaction with inpatient care and hospital readmission within 30 days. Am J Manag Care (2011) 2.27
Perceived discrimination and reported delay of pharmacy prescriptions and medical tests. J Gen Intern Med (2005) 2.25
Changing gender prevalence of stone disease. J Urol (2007) 2.25
New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol (2011) 2.21
Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol (2009) 2.14
PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol (2009) 2.13
Relationship between cardiac rehabilitation and long-term risks of death and myocardial infarction among elderly Medicare beneficiaries. Circulation (2009) 2.11
Geographic variation in carotid revascularization among Medicare beneficiaries, 2003-2006. Arch Intern Med (2010) 2.08
Urinary diversion in patients with spinal cord injury in the United States. Urology (2012) 2.03
High provider volume is associated with lower rate of secondary therapies after definitive radiotherapy for localized prostate cancer. Eur Urol (2007) 2.02
Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol (2008) 1.95
Clinical effectiveness of implantable cardioverter-defibrillators among medicare beneficiaries with heart failure. Circ Heart Fail (2009) 1.95
Promoting quality: the health-care organization from a management perspective. Int J Qual Health Care (2007) 1.94
uPM3, a new molecular urine test for the detection of prostate cancer. Urology (2004) 1.91
Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res (2008) 1.90
Patient satisfaction and its relationship with clinical quality and inpatient mortality in acute myocardial infarction. Circ Cardiovasc Qual Outcomes (2010) 1.88
Early and long-term outcomes of heart failure in elderly persons, 2001-2005. Arch Intern Med (2008) 1.88
Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. J Urol (2008) 1.86
Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol (2012) 1.80
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.76
High radical prostatectomy surgical volume is related to lower radical prostatectomy total hospital charges. Eur Urol (2006) 1.76
Medicine. A portfolio model of drug development for tuberculosis. Science (2006) 1.75
Use of larger versus smaller drug-safety databases before regulatory approval: the trade-offs. Health Aff (Millwood) (2008) 1.74
Metaanalysis and review of heart failure disease management randomized controlled clinical trials. Am Heart J (2005) 1.71
Impact of heart failure on patients undergoing major noncardiac surgery. Anesthesiology (2008) 1.71
Reducing the costs of phase III cardiovascular clinical trials. Am Heart J (2005) 1.69
Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol (2005) 1.69
Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. BJU Int (2007) 1.68
Geographic variations in the use of medical and surgical therapies for benign prostatic hyperplasia. J Urol (2006) 1.67
The effect of dementia on outcomes and process of care for Medicare beneficiaries admitted with acute myocardial infarction. J Am Geriatr Soc (2004) 1.66
Prostate-specific antigen screening among young men in the United States. Cancer (2008) 1.66
Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res (2006) 1.65
The correlation between patient characteristics and expectations of benefit from Phase I clinical trials. Cancer (2003) 1.65
The aging male population and medical care for benign prostatic hyperplasia in Canada. Can Urol Assoc J (2010) 1.63
Process of care performance measures and long-term outcomes in patients hospitalized with heart failure. Med Care (2010) 1.62
Regionalization of percutaneous transluminal coronary angioplasty and implications for patient travel distance. JAMA (2004) 1.59
Trends in health care resource use for hepatitis C virus infection in the United States. Hepatology (2005) 1.58
Partial cystectomy does not undermine cancer control in appropriately selected patients with urothelial carcinoma of the bladder: a population-based matched analysist. Urology (2009) 1.58
The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experience. Urology (2012) 1.57
Medical costs of abnormal serum sodium levels. J Am Soc Nephrol (2008) 1.56
A multinational review of recent trends and reports in dementia caregiver burden. Alzheimer Dis Assoc Disord (2004) 1.55
The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. J Card Fail (2004) 1.54
Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study. Pharmacoepidemiol Drug Saf (2005) 1.52
State-mandated continuing medical education and the use of proven therapies in patients with an acute myocardial infarction. J Am Coll Cardiol (2004) 1.52
Poor overall survival in septa- and octogenarian patients after radical prostatectomy and radiotherapy for prostate cancer: a population-based study of 6183 men. Eur Urol (2007) 1.51
Community hospital oversight of clinical investigators' financial relationships. IRB (2009) 1.51
Survival after radical prostatectomy and radiotherapy for prostate cancer: a population-based study. Can Urol Assoc J (2009) 1.51
Radical versus partial nephrectomy: effect on overall and noncancer mortality. Cancer (2009) 1.51
Spending on postapproval drug safety. Health Aff (Millwood) (2006) 1.50
Patient reactions to confidentiality, liability, and financial aspects of informed consent in cardiology research. Circ Cardiovasc Qual Outcomes (2010) 1.50
Implications of pharmacogenomics for drug development and clinical practice. Arch Intern Med (2005) 1.48
Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods (2009) 1.48